Top

Published in:

01-05-2021 | Insulins | Review

Defining the underlying defect in insulin action in type 2 diabetes

Authors: Thiago M. Batista, Nida Haider, C. Ronald Kahn

Published in: Diabetologia | Issue 5/2021

Abstract

Insulin resistance is one of the earliest defects in the pathogenesis of type 2 diabetes. Over the past 50 years, elucidation of the insulin signalling network has provided important mechanistic insights into the abnormalities of glucose, lipid and protein metabolism that underlie insulin resistance. In classical target tissues (liver, muscle and adipose tissue), insulin binding to its receptor initiates a broad signalling cascade mediated by changes in phosphorylation, gene expression and vesicular trafficking that result in increased nutrient utilisation and storage, and suppression of catabolic processes. Insulin receptors are also expressed in non-classical targets, such as the brain and endothelial cells, where it helps regulate appetite, energy expenditure, reproductive hormones, mood/behaviour and vascular function. Recent progress in cell biology and unbiased molecular profiling by mass spectrometry and DNA/RNA-sequencing has provided a unique opportunity to dissect the determinants of insulin resistance in type 2 diabetes and the metabolic syndrome; best studied are extrinsic factors, such as circulating lipids, amino acids and other metabolites and exosomal microRNAs. More challenging has been defining the cell-intrinsic factors programmed by genetics and epigenetics that underlie insulin resistance. In this regard, studies using human induced pluripotent stem cells and tissues point to cell-autonomous alterations in signalling super-networks, involving changes in phosphorylation and gene expression both inside and outside the canonical insulin signalling pathway. Understanding how these multi-layered molecular networks modulate insulin action and metabolism in different tissues will open new avenues for therapy and prevention of type 2 diabetes and its associated pathologies.

Graphical abstract

Available only for authorised users

Macleod JJR (1922) Treatment of diabetes mellitus by pancreatic extracts. Can Med Assoc J 12(6):425–426

Himsworth HP (2013) Diabetes mellitus: its differentiation into insulin-sensitive and insulin-insensitive types. 1936. Int J Epidemiol 42(6):1594–1598. https://doi.org/10.1093/ije/dyt203CrossRefPubMed

Freychet P, Roth J, Neville DM Jr (1971) Insulin receptors in the liver: specific binding of (125 I)insulin to the plasma membrane and its relation to insulin bioactivity. Proc Natl Acad Sci U S A 68(8):1833–1837. https://doi.org/10.1073/pnas.68.8.1833CrossRefPubMedPubMedCentral

Kasuga M, Zick Y, Blithe DL, Crettaz M, Kahn CR (1982) Insulin stimulates tyrosine phosphorylation of the insulin receptor in a cell-free system. Nature 298(5875):667–669. https://doi.org/10.1038/298667a0CrossRefPubMed

Chevalier S, Burgess SC, Malloy CR, Gougeon R, Marliss EB, Morais JA (2006) The greater contribution of gluconeogenesis to glucose production in obesity is related to increased whole-body protein catabolism. Diabetes 55(3):675–681. https://doi.org/10.2337/diabetes.55.03.06.db05-1117CrossRefPubMed

Perry RJ, Camporez JP, Kursawe R et al (2015) Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell 160(4):745–758. https://doi.org/10.1016/j.cell.2015.01.012CrossRefPubMedPubMedCentral

Seino S, Seino M, Nishi S, Bell GI (1989) Structure of the human insulin receptor gene and characterization of its promoter. Proc Natl Acad Sci U S A 86(1):114–118. https://doi.org/10.1073/pnas.86.1.114CrossRefPubMedPubMedCentral

Belfiore A, Malaguarnera R, Vella V et al (2017) Insulin receptor isoforms in physiology and disease: an updated view. Endocr Rev 38(5):379–431. https://doi.org/10.1210/er.2017-00073CrossRefPubMedPubMedCentral

Cai W, Sakaguchi M, Kleinridders A et al (2017) Domain-dependent effects of insulin and IGF-1 receptors on signalling and gene expression. Nat Commun 8:14892. https://doi.org/10.1038/ncomms14892CrossRefPubMedPubMedCentral

10.

Urso B, Cope DL, Kalloo-Hosein HE et al (1999) Differences in signaling properties of the cytoplasmic domains of the insulin receptor and insulin-like growth factor receptor in 3T3-L1 adipocytes. J Biol Chem 274(43):30864–30873. https://doi.org/10.1074/jbc.274.43.30864CrossRefPubMed

11.

Scapin G, Dandey VP, Zhang Z et al (2018) Structure of the insulin receptor-insulin complex by single-particle cryo-EM analysis. Nature 556(7699):122–125. https://doi.org/10.1038/nature26153CrossRefPubMedPubMedCentral

12.

Uchikawa E, Choi E, Shang G, Yu H, Bai XC (2019) Activation mechanism of the insulin receptor revealed by cryo-EM structure of the fully liganded receptor-ligand complex. eLife 8. https://doi.org/10.7554/eLife.48630

13.

Thirone AC, Huang C, Klip A (2006) Tissue-specific roles of IRS proteins in insulin signaling and glucose transport. Trends Endocrinol Metab 17(2):72–78. https://doi.org/10.1016/j.tem.2006.01.005CrossRefPubMed

14.

Araki E, Lipes MA, Patti ME et al (1994) Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 372(6502):186–190. https://doi.org/10.1038/372186a0CrossRefPubMed

15.

Kaburagi Y, Satoh S, Tamemoto H et al (1997) Role of insulin receptor substrate-1 and pp60 in the regulation of insulin-induced glucose transport and GLUT4 translocation in primary adipocytes. J Biol Chem 272(41):25839–25844. https://doi.org/10.1074/jbc.272.41.25839CrossRefPubMed

16.

Withers DJ, Gutierrez JS, Towery H et al (1998) Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391(6670):900–904. https://doi.org/10.1038/36116CrossRefPubMed

17.

Rabiee A, Kruger M, Ardenkjaer-Larsen J, Kahn CR, Emanuelli B (2018) Distinct signalling properties of insulin receptor substrate (IRS)-1 and IRS-2 in mediating insulin/IGF-1 action. Cell Signal 47:1–15. https://doi.org/10.1016/j.cellsig.2018.03.003CrossRefPubMedPubMedCentral

18.

Ussar S, Bezy O, Bluher M, Kahn CR (2012) Glypican-4 enhances insulin signaling via interaction with the insulin receptor and serves as a novel adipokine. Diabetes 61(9):2289–2298. https://doi.org/10.2337/db11-1395CrossRefPubMedPubMedCentral

19.

Maddux BA, Goldfine ID (2000) Membrane glycoprotein PC-1 inhibition of insulin receptor function occurs via direct interaction with the receptor alpha-subunit. Diabetes 49(1):13–19. https://doi.org/10.2337/diabetes.49.1.13CrossRefPubMed

20.

Batista TM, Dagdeviren S, Carroll SH et al (2020) Arrestin domain-containing 3 (Arrdc3) modulates insulin action and glucose metabolism in liver. Proc Natl Acad Sci U S A 117(12):6733–6740. https://doi.org/10.1073/pnas.1922370117CrossRefPubMedPubMedCentral

21.

Sakaguchi M, Cai W, Wang CH et al (2019) FoxK1 and FoxK2 in insulin regulation of cellular and mitochondrial metabolism. Nat Commun 10(1):1582. https://doi.org/10.1038/s41467-019-09418-0CrossRefPubMedPubMedCentral

22.

Choi E, Zhang X, Xing C, Yu H (2016) Mitotic checkpoint regulators control insulin signaling and metabolic homeostasis. Cell 166(3):567–581. https://doi.org/10.1016/j.cell.2016.05.074CrossRefPubMedPubMedCentral

23.

Mora A, Komander D, van Aalten DM, Alessi DR (2004) PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol 15(2):161–170. https://doi.org/10.1016/j.semcdb.2003.12.022CrossRefPubMed

24.

Bilanges B, Posor Y, Vanhaesebroeck B (2019) PI3K isoforms in cell signalling and vesicle trafficking. Nat Rev Mol Cell Biol 20(9):515–534. https://doi.org/10.1038/s41580-019-0129-zCrossRefPubMed

25.

Manning BD, Toker A (2017) AKT/PKB signaling: navigating the network. Cell 169(3):381–405. https://doi.org/10.1016/j.cell.2017.04.001CrossRefPubMedPubMedCentral

26.

Feng J, Park J, Cron P, Hess D, Hemmings BA (2004) Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol Chem 279(39):41189–41196. https://doi.org/10.1074/jbc.M406731200CrossRefPubMed

27.

Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378(6559):785–789. https://doi.org/10.1038/378785a0CrossRefPubMed

28.

Matsumoto M, Pocai A, Rossetti L, Depinho RA, Accili D (2007) Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell Metab 6(3):208–216. https://doi.org/10.1016/j.cmet.2007.08.006CrossRefPubMed

29.

Nakae J, Barr V, Accili D (2000) Differential regulation of gene expression by insulin and IGF-1 receptors correlates with phosphorylation of a single amino acid residue in the forkhead transcription factor FKHR. EMBO J 19(5):989–996. https://doi.org/10.1093/emboj/19.5.989CrossRefPubMedPubMedCentral

30.

O’Neill BT, Lee KY, Klaus K et al (2016) Insulin and IGF-1 receptors regulate FoxO-mediated signaling in muscle proteostasis. J Clin Invest 126(9):3433–3446. https://doi.org/10.1172/JCI86522CrossRefPubMedPubMedCentral

31.

Sancak Y, Thoreen CC, Peterson TR et al (2007) PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25(6):903–915. https://doi.org/10.1016/j.molcel.2007.03.003CrossRefPubMed

32.

Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J (2002) Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A 99(21):13571–13576. https://doi.org/10.1073/pnas.202476899CrossRefPubMedPubMedCentral

33.

Karlsson HK, Zierath JR, Kane S, Krook A, Lienhard GE, Wallberg-Henriksson H (2005) Insulin-stimulated phosphorylation of the Akt substrate AS160 is impaired in skeletal muscle of type 2 diabetic subjects. Diabetes 54(6):1692–1697. https://doi.org/10.2337/diabetes.54.6.1692CrossRefPubMed

34.

Sano H, Kane S, Sano E et al (2003) Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. J Biol Chem 278(17):14599–14602. https://doi.org/10.1074/jbc.C300063200CrossRefPubMed

35.

Humphrey SJ, Azimifar SB, Mann M (2015) High-throughput phosphoproteomics reveals in vivo insulin signaling dynamics. Nat Biotechnol 33(9):990–995. https://doi.org/10.1038/nbt.3327CrossRefPubMed

36.

Humphrey SJ, Yang G, Yang P et al (2013) Dynamic adipocyte phosphoproteome reveals that Akt directly regulates mTORC2. Cell Metab 17(6):1009–1020. https://doi.org/10.1016/j.cmet.2013.04.010CrossRefPubMedPubMedCentral

37.

Batista TM, Garcia-Martin R, Cai W et al (2019) Multi-dimensional transcriptional remodeling by physiological insulin in vivo. Cell Rep 26(12):3429–3443 e3423. https://doi.org/10.1016/j.celrep.2019.02.081CrossRefPubMedPubMedCentral

38.

Karlsson HK, Chibalin AV, Koistinen HA et al (2009) Kinetics of GLUT4 trafficking in rat and human skeletal muscle. Diabetes 58(4):847–854. https://doi.org/10.2337/db08-1539CrossRefPubMedPubMedCentral

39.

Bruss MD, Arias EB, Lienhard GE, Cartee GD (2005) Increased phosphorylation of Akt substrate of 160 kDa (AS160) in rat skeletal muscle in response to insulin or contractile activity. Diabetes 54(1):41–50. https://doi.org/10.2337/diabetes.54.1.41CrossRefPubMed

40.

Huang X, Vaag A, Hansson M, Weng J, Laurila E, Groop L (2000) Impaired insulin-stimulated expression of the glycogen synthase gene in skeletal muscle of type 2 diabetic patients is acquired rather than inherited. J Clin Endocrinol Metab 85(4):1584–1590. https://doi.org/10.1210/jcem.85.4.6535CrossRefPubMed

41.

Sears DD, Hsiao G, Hsiao A et al (2009) Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitization. Proc Natl Acad Sci U S A 106(44):18745–18750. https://doi.org/10.1073/pnas.0903032106CrossRefPubMedPubMedCentral

42.

Stump CS, Short KR, Bigelow ML, Schimke JM, Nair KS (2003) Effect of insulin on human skeletal muscle mitochondrial ATP production, protein synthesis, and mRNA transcripts. Proc Natl Acad Sci U S A 100(13):7996–8001. https://doi.org/10.1073/pnas.1332551100CrossRefPubMedPubMedCentral

43.

O’Brien RM, Granner DK (1991) Regulation of gene expression by insulin. Biochem J 278(Pt 3):609–619. https://doi.org/10.1042/bj2780609CrossRefPubMedPubMedCentral

44.

Brunet A, Bonni A, Zigmond MJ et al (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96(6):857–868. https://doi.org/10.1016/S0092-8674(00)80595-4CrossRefPubMed

45.

Brunet A, Park J, Tran H, Hu LS, Hemmings BA, Greenberg ME (2001) Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol 21(3):952–965. https://doi.org/10.1128/MCB.21.3.952-965.2001CrossRefPubMedPubMedCentral

46.

Haeusler RA, Hartil K, Vaitheesvaran B et al (2014) Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors. Nat Commun 5:5190. https://doi.org/10.1038/ncomms6190CrossRefPubMed

47.

Sandri M, Sandri C, Gilbert A et al (2004) Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117(3):399–412. https://doi.org/10.1016/s0092-8674(04)00400-3CrossRefPubMedPubMedCentral

48.

Nakae J, Cao Y, Oki M et al (2008) Forkhead transcription factor FoxO1 in adipose tissue regulates energy storage and expenditure. Diabetes 57(3):563–576. https://doi.org/10.2337/db07-0698CrossRefPubMed

49.

I OS, Zhang W, Wasserman DH et al (2015) FoxO1 integrates direct and indirect effects of insulin on hepatic glucose production and glucose utilization. Nat Commun 6:7079. https://doi.org/10.1038/ncomms8079CrossRef

50.

Lu M, Wan M, Leavens KF et al (2012) Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat Med 18(3):388–395. https://doi.org/10.1038/nm.2686CrossRefPubMedPubMedCentral

51.

O’Neill BT, Bhardwaj G, Penniman CM et al (2019) FoxO transcription factors are critical regulators of diabetes-related muscle atrophy. Diabetes 68(3):556–570. https://doi.org/10.2337/db18-0416CrossRefPubMed

52.

He L, Gomes AP, Wang X et al (2018) mTORC1 promotes metabolic reprogramming by the suppression of GSK3-dependent Foxk1 phosphorylation. Mol Cell 70(5):949–960 e944. https://doi.org/10.1016/j.molcel.2018.04.024CrossRefPubMedPubMedCentral

53.

Sukonina V, Ma H, Zhang W et al (2019) FOXK1 and FOXK2 regulate aerobic glycolysis. Nature 566(7743):279–283. https://doi.org/10.1038/s41586-019-0900-5CrossRefPubMed

54.

Shimano H, Sato R (2017) SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology. Nat Rev Endocrinol 13(12):710–730. https://doi.org/10.1038/nrendo.2017.91CrossRefPubMed

55.

Goldfine ID, Smith GJ (1976) Binding of insulin to isolated nuclei. Proc Natl Acad Sci U S A 73(5):1427–1431. https://doi.org/10.1073/pnas.73.5.1427CrossRefPubMedPubMedCentral

56.

Hancock ML, Meyer RC, Mistry M et al (2019) Insulin receptor associates with promoters genome-wide and regulates gene expression. Cell 177(3):722–736 e722. https://doi.org/10.1016/j.cell.2019.02.030CrossRefPubMedPubMedCentral

57.

Zheng Y, Ley SH, Hu FB (2018) Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 14(2):88–98. https://doi.org/10.1038/nrendo.2017.151CrossRefPubMed

58.

Roden M, Shulman GI (2019) The integrative biology of type 2 diabetes. Nature 576(7785):51–60. https://doi.org/10.1038/s41586-019-1797-8CrossRefPubMed

59.

Zaharia OP, Strassburger K, Strom A et al (2019) Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 7(9):684–694. https://doi.org/10.1016/S2213-8587(19)30187-1CrossRefPubMed

60.

Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR (1992) Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 340(8825):925–929. https://doi.org/10.1016/0140-6736(92)92814-VCrossRefPubMed

61.

Eriksson J, Franssila-Kallunki A, Ekstrand A et al (1989) Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 321(6):337–343. https://doi.org/10.1056/NEJM198908103210601CrossRefPubMed

62.

Rothman DL, Magnusson I, Cline G et al (1995) Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 92(4):983–987CrossRefPubMedPubMedCentral

63.

Cline GW, Petersen KF, Krssak M et al (1999) Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 341(4):240–246. https://doi.org/10.1056/NEJM199907223410404CrossRefPubMed

64.

Mootha VK, Lindgren CM, Eriksson KF et al (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34(3):267–273. https://doi.org/10.1038/ng1180CrossRefPubMed

65.

Patti ME, Butte AJ, Crunkhorn S et al (2003) Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A 100(14):8466–8471. https://doi.org/10.1073/pnas.1032913100CrossRefPubMedPubMedCentral

66.

Gregor MF, Hotamisligil GS (2010) Inflammatory mechanisms in obesity. Annu Rev Immunol 29:415–445CrossRef

67.

Newgard CB (2012) Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab 15(5):606–614. https://doi.org/10.1016/j.cmet.2012.01.024CrossRefPubMedPubMedCentral

68.

Samuel VT, Shulman GI (2012) Mechanisms for insulin resistance: common threads and missing links. Cell 148(5):852–871. https://doi.org/10.1016/j.cell.2012.02.017CrossRefPubMedPubMedCentral

69.

Dunaif A, Xia J, Book CB, Schenker E, Tang Z (1995) Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 96(2):801–810. https://doi.org/10.1172/JCI118126CrossRefPubMedPubMedCentral

70.

Itani SI, Ruderman NB, Schmieder F, Boden G (2002) Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes 51(7):2005–2011CrossRefPubMed

71.

Lyu K, Zhang Y, Zhang D et al (2020) A membrane-bound diacylglycerol species induces PKC-mediated hepatic insulin resistance. Cell Metab 32(4):654–664 e655. https://doi.org/10.1016/j.cmet.2020.08.001CrossRefPubMedPubMedCentral

72.

Moeschel K, Beck A, Weigert C et al (2004) Protein kinase C-zeta-induced phosphorylation of Ser318 in insulin receptor substrate-1 (IRS-1) attenuates the interaction with the insulin receptor and the tyrosine phosphorylation of IRS-1. J Biol Chem 279(24):25157–25163. https://doi.org/10.1074/jbc.M402477200CrossRefPubMed

73.

Weigert C, Hennige AM, Brischmann T et al (2005) The phosphorylation of Ser318 of insulin receptor substrate 1 is not per se inhibitory in skeletal muscle cells but is necessary to trigger the attenuation of the insulin-stimulated signal. J Biol Chem 280(45):37393–37399CrossRefPubMed

74.

Paz K, Hemi R, LeRoith D et al (1997) A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem 272(47):29911–29918. https://doi.org/10.1074/jbc.272.47.29911CrossRefPubMed

75.

Glass CK, Olefsky JM (2012) Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab 15(5):635–645. https://doi.org/10.1016/j.cmet.2012.04.001CrossRefPubMedPubMedCentral

76.

Johnson AM, Olefsky JM (2013) The origins and drivers of insulin resistance. Cell 152(4):673–684. https://doi.org/10.1016/j.cell.2013.01.041CrossRefPubMed

77.

Sun K, Kusminski CM, Scherer PE (2011) Adipose tissue remodeling and obesity. J Clin Invest 121(6):2094–2101. https://doi.org/10.1172/JCI45887CrossRefPubMedPubMedCentral

78.

Lumeng CN, Bodzin JL, Saltiel AR (2007) Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117(1):175–184. https://doi.org/10.1172/JCI29881CrossRefPubMedPubMedCentral

79.

Osborn O, Olefsky JM (2012) The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 18(3):363–374. https://doi.org/10.1038/nm.2627CrossRefPubMed

80.

Lebrun P, Van Obberghen E (2008) SOCS proteins causing trouble in insulin action. Acta Physiol 192(1):29–36. https://doi.org/10.1111/j.1748-1716.2007.01782.xCrossRef

81.

Liu J, Ibi D, Taniguchi K et al (2016) Inflammation improves glucose homeostasis through IKKbeta-XBP1s interaction. Cell 167(4):1052–1066 e1018. https://doi.org/10.1016/j.cell.2016.10.015CrossRefPubMedPubMedCentral

82.

Raciti M, Lotti LV, Valia S, Pulcinelli FM, Di Renzo L (2012) JNK2 is activated during ER stress and promotes cell survival. Cell Death Dis 3:e429. https://doi.org/10.1038/cddis.2012.167CrossRefPubMedPubMedCentral

83.

Cummings NE, Williams EM, Kasza I et al (2018) Restoration of metabolic health by decreased consumption of branched-chain amino acids. J Physiol 596(4):623–645. https://doi.org/10.1113/JP275075CrossRefPubMed

84.

Newgard CB, An J, Bain JR et al (2009) A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 9(4):311–326. https://doi.org/10.1016/j.cmet.2009.02.002CrossRefPubMedPubMedCentral

85.

Saad MJ, Santos A, Prada PO (2016) Linking gut microbiota and inflammation to obesity and insulin resistance. Physiology 31(4):283–293. https://doi.org/10.1152/physiol.00041.2015CrossRefPubMed

86.

Copps KD, White MF (2012) Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia 55(10):2565–2582. https://doi.org/10.1007/s00125-012-2644-8CrossRefPubMedPubMedCentral

87.

Li M, Vienberg SG, Bezy O, O’Neill BT, Kahn CR (2015) Role of PKCdelta in insulin sensitivity and skeletal muscle metabolism. Diabetes 64(12):4023–4032. https://doi.org/10.2337/db14-1891CrossRefPubMedPubMedCentral

88.

Thomou T, Mori MA, Dreyfuss JM et al (2017) Adipose-derived circulating miRNAs regulate gene expression in other tissues. Nature 542(7642):450–455. https://doi.org/10.1038/nature21365CrossRefPubMedPubMedCentral

89.

Ying W, Riopel M, Bandyopadhyay G et al (2017) Adipose tissue macrophage-derived exosomal miRNAs can modulate in vivo and in vitro insulin sensitivity. Cell 171(2):372–384 e312. https://doi.org/10.1016/j.cell.2017.08.035CrossRefPubMed

90.

Bouzakri K, Roques M, Gual P et al (2003) Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes. Diabetes 52(6):1319–1325. https://doi.org/10.2337/diabetes.52.6.1319CrossRefPubMed

91.

Cozzone D, Frojdo S, Disse E et al (2008) Isoform-specific defects of insulin stimulation of Akt/protein kinase B (PKB) in skeletal muscle cells from type 2 diabetic patients. Diabetologia 51(3):512–521. https://doi.org/10.1007/s00125-007-0913-8CrossRefPubMed

92.

Gaster M, Brusgaard K, Handberg A, Hojlund K, Wojtaszewski JF, Beck-Nielsen H (2004) The primary defect in glycogen synthase activity is not based on increased glycogen synthase kinase-3alpha activity in diabetic myotubes. Biochem Biophys Res Commun 319(4):1235–1240. https://doi.org/10.1016/j.bbrc.2004.05.109CrossRefPubMed

93.

Gaster M, Petersen I, Hojlund K, Poulsen P, Beck-Nielsen H (2002) The diabetic phenotype is conserved in myotubes established from diabetic subjects: evidence for primary defects in glucose transport and glycogen synthase activity. Diabetes 51(4):921–927. https://doi.org/10.2337/diabetes.51.4.921CrossRefPubMed

94.

McIntyre EA, Halse R, Yeaman SJ, Walker M (2004) Cultured muscle cells from insulin-resistant type 2 diabetes patients have impaired insulin, but normal 5-amino-4-imidazolecarboxamide riboside-stimulated, glucose uptake. J Clin Endocrinol Metab 89(7):3440–3448. https://doi.org/10.1210/jc.2003-031919CrossRefPubMed

95.

Burkart AM, Tan K, Warren L et al (2016) Insulin resistance in human iPS cells reduces mitochondrial size and function. Sci Rep 6:22788. https://doi.org/10.1038/srep22788CrossRefPubMedPubMedCentral

96.

Iovino S, Burkart AM, Kriauciunas K et al (2014) Genetic insulin resistance is a potent regulator of gene expression and proliferation in human iPS cells. Diabetes 63(12):4130–4142. https://doi.org/10.2337/db14-0109CrossRefPubMedPubMedCentral

97.

Iovino S, Burkart AM, Warren L, Patti ME, Kahn CR (2016) Myotubes derived from human-induced pluripotent stem cells mirror in vivo insulin resistance. Proc Natl Acad Sci U S A 113(7):1889–1894. https://doi.org/10.1073/pnas.1525665113CrossRefPubMedPubMedCentral

98.

Gupta MK, Vethe H, Softic S et al (2020) Leptin receptor signaling regulates protein synthesis pathways and neuronal differentiation in pluripotent stem cells. Stem Cell Rep 15(5):1067–1079. https://doi.org/10.1016/j.stemcr.2020.10.001CrossRef

99.

Teo AK, Windmueller R, Johansson BB et al (2013) Derivation of human induced pluripotent stem cells from patients with maturity onset diabetes of the young. J Biol Chem 288(8):5353–5356. https://doi.org/10.1074/jbc.C112.428979CrossRefPubMedPubMedCentral

100.

Batista TM, Jayavelu AK, Wewer Albrechtsen NJ et al (2020) A cell-autonomous signature of dysregulated protein phosphorylation underlies muscle insulin resistance in type 2 diabetes. Cell Metab 32:844–859. https://doi.org/10.1016/j.cmet.2020.08.007CrossRefPubMedPubMedCentral

101.

Taniguchi CM, Emanuelli B, Kahn CR (2006) Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7(2):85–96. https://doi.org/10.1038/nrm1837CrossRefPubMed

102.

Barres R, Osler ME, Yan J et al (2009) Non-CpG methylation of the PGC-1alpha promoter through DNMT3B controls mitochondrial density. Cell Metab 10(3):189–198. https://doi.org/10.1016/j.cmet.2009.07.011CrossRefPubMed

103.

Ribel-Madsen R, Fraga MF, Jacobsen S et al (2012) Genome-wide analysis of DNA methylation differences in muscle and fat from monozygotic twins discordant for type 2 diabetes. PLoS One 7(12):e51302. https://doi.org/10.1371/journal.pone.0051302CrossRefPubMedPubMedCentral

104.

Frobel J, Hemeda H, Lenz M et al (2014) Epigenetic rejuvenation of mesenchymal stromal cells derived from induced pluripotent stem cells. Stem Cell Rep 3(3):414–422. https://doi.org/10.1016/j.stemcr.2014.07.003CrossRef

105.

Vujkovic M, Keaton JM, Lynch JA et al (2020) Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. Nat Genet 52(7):680–691. https://doi.org/10.1038/s41588-020-0637-yCrossRefPubMedPubMedCentral

106.

Miguel-Escalada I, Bonas-Guarch S, Cebola I et al (2019) Human pancreatic islet three-dimensional chromatin architecture provides insights into the genetics of type 2 diabetes. Nat Genet 51(7):1137–1148. https://doi.org/10.1038/s41588-019-0457-0CrossRefPubMedPubMedCentral

107.

Williams K, Ingerslev LR, Bork-Jensen J et al (2020) Skeletal muscle enhancer interactions identify genes controlling whole-body metabolism. Nat Commun 11(1):2695. https://doi.org/10.1038/s41467-020-16537-6CrossRefPubMedPubMedCentral

108.

Claussnitzer M, Dankel SN, Kim KH et al (2015) FTO obesity variant circuitry and adipocyte browning in humans. N Engl J Med 373(10):895–907. https://doi.org/10.1056/NEJMoa1502214CrossRefPubMedPubMedCentral

109.

Manning AK, Hivert MF, Scott RA et al (2012) A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet 44(6):659–669. https://doi.org/10.1038/ng.2274CrossRefPubMedPubMedCentral

110.

Nigi L, Grieco GE, Ventriglia G et al (2018) MicroRNAs as regulators of insulin signaling: research updates and potential therapeutic perspectives in type 2 diabetes. Int J Mol Sci 19(12):3705. https://doi.org/10.3390/ijms19123705CrossRefPubMedCentral

111.

Massart J, Sjogren RJO, Lundell LS et al (2017) Altered miR-29 expression in type 2 diabetes influences glucose and lipid metabolism in skeletal muscle. Diabetes 66(7):1807–1818. https://doi.org/10.2337/db17-0141CrossRefPubMed

112.

Katayama M, Wiklander OPB, Fritz T et al (2018) Circulating exosomal miR-20b-5p is elevated in type 2 diabetes and could impair insulin action in human skeletal muscle. Diabetes 68(3):515–526. https://doi.org/10.2337/db18-0470CrossRefPubMed

113.

Henriksen TI, Davidsen PK, Pedersen M et al (2017) Dysregulation of a novel miR-23b/27b-p53 axis impairs muscle stem cell differentiation of humans with type 2 diabetes. Mol Metab 6(7):770–779. https://doi.org/10.1016/j.molmet.2017.04.006CrossRefPubMedPubMedCentral

114.

Yang L, Li P, Yang W et al (2016) Integrative transcriptome analyses of metabolic responses in mice define pivotal LncRNA metabolic regulators. Cell Metab 24(4):627–639. https://doi.org/10.1016/j.cmet.2016.08.019CrossRefPubMedPubMedCentral

115.

Carter G, Miladinovic B, Patel AA, Deland L, Mastorides S, Patel NA (2015) Circulating long noncoding RNA GAS5 levels are correlated to prevalence of type 2 diabetes mellitus. BBA Clin 4:102–107. https://doi.org/10.1016/j.bbacli.2015.09.001CrossRefPubMedPubMedCentral

116.

Shi Y, Parag S, Patel R et al (2019) Stabilization of lncRNA GAS5 by a small molecule and its implications in diabetic adipocytes. Cell Chem Biol 26(3):319–330 e316. https://doi.org/10.1016/j.chembiol.2018.11.012CrossRefPubMed

117.

Pihlajamaki J, Lerin C, Itkonen P et al (2011) Expression of the splicing factor gene SFRS10 is reduced in human obesity and contributes to enhanced lipogenesis. Cell Metab 14(2):208–218. https://doi.org/10.1016/j.cmet.2011.06.007CrossRefPubMedPubMedCentral

118.

Weyer C, Funahashi T, Tanaka S et al (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86(5):1930–1935. https://doi.org/10.1210/jcem.86.5.7463CrossRefPubMed

119.

Lynes MD, Leiria LO, Lundh M et al (2017) The cold-induced lipokine 12,13-diHOME promotes fatty acid transport into brown adipose tissue. Nat Med 23(5):631–637. https://doi.org/10.1038/nm.4297CrossRefPubMedPubMedCentral

120.

Yore MM, Syed I, Moraes-Vieira PM et al (2014) Discovery of a class of endogenous mammalian lipids with anti-diabetic and anti-inflammatory effects. Cell 159(2):318–332. https://doi.org/10.1016/j.cell.2014.09.035CrossRefPubMedPubMedCentral

Title: Defining the underlying defect in insulin action in type 2 diabetes
Authors: Thiago M. Batista
Nida Haider
C. Ronald Kahn
Publication date: 01-05-2021
Publisher: Springer Berlin Heidelberg
Keywords: Insulins
Insulins
Type 2 Diabetes
Published in: Diabetologia / Issue 5/2021
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-021-05415-5

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Graphical abstract

Please log in to get access to this content

Other articles of this Issue 5/2021

A global perspective on the issue of access to insulin

The consequences of hypoglycaemia

Biphasic dynamics of beta cell mass in a mouse model of congenital hyperinsulinism: implications for type 2 diabetes

Potential diabetes overtreatment and risk of adverse events among older adults in Ontario: a population-based study

Size for gestational age affects the risk for type 1 diabetes in children and adolescents: a Swedish national case–control study

Transforming type 1 diabetes: the next wave of innovation

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage